> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Ocuvex Resubmits NDA for Glaucoma Drug
- URL: https://www.fdaweb.com/ocuvex-resubmits-nda-for-glaucoma-drug/
- Published: 2025-11-20T12:00:00.000Z
- Updated: 2026-09-14T15:27:12.000Z
- Author: David McFarland
- Tags: Drugs, #legacy-id-D5160261

Sun Pharma Advanced Research Company (SPARC) says that Ocuvex Therapeutics has resubmitted an NDA for PDP-716, more than two years after FDA the agency issued a complete response letter (CRL) tied to manufacturing deficiencies at a third-party supplier. The agency 7/2023-issued CRL cited inspection-related issues at an external active pharmaceutical ingredient (API) manufacturing site.

In both a 2023 notice about the CRL and the latest update, SPARC emphasized that the agency has raised no concerns about the efficacy or safety of PDP-716, a once-daily ophthalmic suspension of brimonidine tartrate 0.35% for treating glaucoma, and developed with SPARC’s TearAct technology. No additional clinical trials have been requested, it adds.

PDP-716 had previously been licensed to Visiox Pharmaceuticals for commercialization outside India and China. Ocuvex is now leading the resubmission effort, according to SPARC.